Inhibitors of the mutant form of kit

Details for Australian Patent Application No. 2004290902 (hide)

Owner Novartis AG

Inventors Buchdunger, Elisabeth; Fabbro, Doriano

Agent Davies Collison Cave

Pub. Number AU-B-2004290902

PCT Pub. Number WO2005/049032

Priority 60/520,714 18.11.03 US

Filing date 17 November 2004

Wipo publication date 2 June 2005

Acceptance publication date 25 September 2008

International Classifications

A61K 31/502 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Event Publications

1 June 2006 PCT application entered the National Phase

  PCT publication WO2005/049032 Priority application(s): WO2005/049032

25 September 2008 Application Accepted

  Published as AU-B-2004290902

22 January 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004290907-Support element

2004290901-Antimicrobial composite material